Your browser doesn't support javascript.
loading
Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort.
Leman, Raphaël; Gaildrat, Pascaline; Le Gac, Gérald; Ka, Chandran; Fichou, Yann; Audrezet, Marie-Pierre; Caux-Moncoutier, Virginie; Caputo, Sandrine M; Boutry-Kryza, Nadia; Léone, Mélanie; Mazoyer, Sylvie; Bonnet-Dorion, Françoise; Sevenet, Nicolas; Guillaud-Bataille, Marine; Rouleau, Etienne; Bressac-de Paillerets, Brigitte; Wappenschmidt, Barbara; Rossing, Maria; Muller, Danielle; Bourdon, Violaine; Revillon, Françoise; Parsons, Michael T; Rousselin, Antoine; Davy, Grégoire; Castelain, Gaia; Castéra, Laurent; Sokolowska, Joanna; Coulet, Florence; Delnatte, Capucine; Férec, Claude; Spurdle, Amanda B; Martins, Alexandra; Krieger, Sophie; Houdayer, Claude.
Afiliação
  • Leman R; Laboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
  • Gaildrat P; Inserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
  • Le Gac G; Normandie Univ, UNICAEN, 14000 Caen, France.
  • Ka C; Inserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
  • Fichou Y; Inserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
  • Audrezet MP; Inserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
  • Caux-Moncoutier V; Inserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
  • Caputo SM; Inserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
  • Boutry-Kryza N; Inserm U830, Institut Curie Centre de Recherches, 75005 Paris, France.
  • Léone M; Université Paris Descartes, Sorbonne Paris Cité, 75005 Paris, France.
  • Mazoyer S; Service de Génétique, Institut Curie, 75005 Paris, France.
  • Bonnet-Dorion F; Service de Génétique, Institut Curie, 75005 Paris, France.
  • Sevenet N; Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, 69000 Lyon, France.
  • Guillaud-Bataille M; Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, 69000 Lyon, France.
  • Rouleau E; Lyon Neuroscience Research Center-CRNL, Inserm U1028, CNRS UMR 5292, University of Lyon, 69008 Lyon, France.
  • Bressac-de Paillerets B; Inserm U916, Département de Pathologie, Laboratoire de Génétique Constitutionnelle, Institut Bergonié, 33000 Bordeaux, France.
  • Wappenschmidt B; Inserm U916, Département de Pathologie, Laboratoire de Génétique Constitutionnelle, Institut Bergonié, 33000 Bordeaux, France.
  • Rossing M; Gustave Roussy, Université Paris-Saclay, Département de Biopathologie, 94805 Villejuif, France.
  • Muller D; Gustave Roussy, Université Paris-Saclay, Département de Biopathologie, 94805 Villejuif, France.
  • Bourdon V; Gustave Roussy, Université Paris-Saclay, Département de Biopathologie, 94805 Villejuif, France.
  • Revillon F; Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, University Hospital of Cologne, 50937 Cologne, Germany.
  • Parsons MT; Centre for Genomic Medicine, Rigshospitalet, University of Copenhagen, 1017 Copenhagen, Denmark.
  • Rousselin A; Laboratoire d'Oncogénétique, Centre Paul Strauss, 67000 Strasbourg, France.
  • Davy G; Laboratoire d'Oncogénétique Moléculaire, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Castelain G; Laboratoire d'Oncogénétique Moléculaire Humaine, Centre Oscar Lambret, 59000 Lille, France.
  • Castéra L; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 4006 Herston, Queensland, Australia.
  • Sokolowska J; Laboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
  • Coulet F; Inserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
  • Delnatte C; Laboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
  • Férec C; Inserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
  • Spurdle AB; Inserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
  • Martins A; Laboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
  • Krieger S; Inserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
  • Houdayer C; Service de Génétique, CHU Nancy, 54035 Nancy, France.
Nucleic Acids Res ; 46(15): 7913-7923, 2018 09 06.
Article em En | MEDLINE | ID: mdl-29750258
ABSTRACT
Variant interpretation is the key issue in molecular diagnosis. Spliceogenic variants exemplify this issue as each nucleotide variant can be deleterious via disruption or creation of splice site consensus sequences. Consequently, reliable in silico prediction of variant spliceogenicity would be a major improvement. Thanks to an international effort, a set of 395 variants studied at the mRNA level and occurring in 5' and 3' consensus regions (defined as the 11 and 14 bases surrounding the exon/intron junction, respectively) was collected for 11 different genes, including BRCA1, BRCA2, CFTR and RHD, and used to train and validate a new prediction protocol named Splicing Prediction in Consensus Elements (SPiCE). SPiCE combines in silico predictions from SpliceSiteFinder-like and MaxEntScan and uses logistic regression to define optimal decision thresholds. It revealed an unprecedented sensitivity and specificity of 99.5 and 95.2%, respectively, and the impact on splicing was correctly predicted for 98.8% of variants. We therefore propose SPiCE as the new tool for predicting variant spliceogenicity. It could be easily implemented in any diagnostic laboratory as a routine decision making tool to help geneticists to face the deluge of variants in the next-generation sequencing era. SPiCE is accessible at (https//sourceforge.net/projects/spicev2-1/).
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Simulação por Computador / Splicing de RNA / Biologia Computacional / Sítios de Splice de RNA Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Simulação por Computador / Splicing de RNA / Biologia Computacional / Sítios de Splice de RNA Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article